Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | BARD1 |
| Variant | E287fs |
| Impact List | frameshift |
| Protein Effect | loss of function |
| Gene Variant Descriptions | BARD1 E287fs results in a change in the amino acid sequence of the Bard1 protein beginning at aa 287 of 777, likely resulting in premature truncation of the functional protein (UniProt.org). E287fs results in decreased Bard1 expression and homology-directed repair activity, increased double-strand DNA breaks, and increased sensitivity to olaparib and cisplatin in cultured cells (PMID: 37688570). |
| Associated Drug Resistance | |
| Category Variants Paths |
BARD1 mutant BARD1 inact mut BARD1 E287fs |
| Transcript | NM_000465.4 |
| gDNA | chr2:g.(214781015_214781016) |
| cDNA | c.(859_858) |
| Protein | p.E287fs |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_000465.4 | chr2:g.(214781015_214781016) | c.(859_858) | p.E287fs | RefSeq | GRCh38/hg38 |
| XM_047445350.1 | chr2:g.(214781015_214781016) | c.(859_858) | p.E287fs | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BARD1 E287fs | neuroblastoma | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a neuroblastoma cell line expressing BARD1 E287fs culture (PMID: 37688570). | 37688570 |
| BARD1 E287fs | neuroblastoma | predicted - sensitive | Olaparib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Lynparza (olaparib) treatment inhibited viability of a neuroblastoma cell line expressing BARD1 E287fs in culture but did not delay tumor growth in a cell line xenograft model (PMID: 37688570). | 37688570 |
| BARD1 E287fs | neuroblastoma | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with the combination of Lynparza (Olaparib) and Platinol (cisplatin) treatment inhibited viability of a neuroblastoma cell line expressing BARD1 E287fs culture (PMID: 37688570). | 37688570 |